In March 2024, the FDA expanded Wegovys approval to include reducing cardiovascular risk in people with obesity and existing cardiovascular diseasea major milestone for these treatments
These injections are effective, but they may not be suitable for everyone
Franklin CC, Krejsa CM, Pierce RH, White CC, Fausto N, Kavanagh TJ
This is especially useful for long-term users who follow a maintenance plan
Energy Expenditure: Semaglutide GLP-1 also activates brown adipose tissue, which burns calories to produce heat, aiding in weight loss through increased energy expenditure
Understanding expiration and beyond-use dates helps you maximize the potency of every dose